{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"The frequency of subjects with Peripheral blood (unsorted) chimerism\\>95% at 56 days will be described.","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"56 days post-transplant","title":"Peripheral Blood Chimerism","type":"SECONDARY","unitOfMeasure":"Participants"}